Persistent infection by high-risk types of human papillomaviruses (HPV) is a necessary cause of cervical cancer, with HPV16 the most prevalent, accounting for more than 50% of reported cases. The virus encodes the E6 and E7 oncoproteins, whose expression is essential for maintenance of the malignant phenotype. To select efficacious siRNAs applicable to RNAi therapy for patients with HPV16 þ cervical cancer, E6 and E7 siRNAs were designed using siDirect computer software, after which 10 compatible with all HPV16 variants were selected, and then extensively examined for RNAi activity and specificity using HPV16 þ and HPV16Àcells. Three siRNAs with the highest RNAi activities toward E6 and E7 expression, as well as specific and potent growth suppression of HPV16 þ cancer cells as low as 1 nM were chosen. Growth suppression was accompanied by accumulation of p53 and p21
Introduction
Cervical cancer is the second most common type of cancer encountered in females, with an incidence rate of up to 18.7 per 100 000. 1 Epidemiological and experimental studies have shown that persistent infections with highrisk types of human papillomaviruses (hrHPVs; HPV16, 18, 31, 33, 45) are a necessary cause of cervical cancer, with HPV16 accounting for approximately 50% of reported cases of HPV-related cervical cancer. These viruses encode the E6 and E7 oncogenes, whose expression is essential for virus replication. [2] [3] [4] Furthermore, deregulated E6 and E7 expression leads to malignant transformation, and is pivotal for maintenance of the malignant phenotype of cervical cancer.
Cellular targets for these hrHPV oncogenes have been investigated, with the p53 tumor suppressor protein the first identified E6 target and still the most important. The E6 protein forms a tertiary complex with E6AP functioning as a ubiquitin ligase and its substrate, p53, which leads to degradation of p53. Other E6 targets include the PDZ family of proteins, such as PSD-95, hDlg and ZO-1, as well as the co-activator p300/CBP. E6 also induces the expression of human telomerase reverse transcriptase (hTERT), a catalytic subunit of human telomerase, whose activity may be involved in immortalization.
Targets of the E7 protein include the pocket protein family of retinoblastoma protein (Rb) and the cyclindependent kinase inhibitors p21 WAF1/CIP1 and p27 KIP1 . [2] [3] [4] Since these molecules are negative regulators of the cell cycle, their inhibition by E7 results in upregulation of genes required for G 1 /S transition and DNA synthesis, which is essential for viral genome replication and amplification. 5 However, E7 also induces genome instability and genetic alterations, which subsequently accumulate and cause transformation of infected cells into malignant cells. Recently, E7 was shown to form a complex with promyelocytic leukemia protein (PML), which has been implicated in controlling cellular senescence as a pro-senescence factor. 6 Because of the strong relationships between the expression of HPV oncogenes and cervical cancer carcinogenesis, several technologies have been applied to target virus oncogenes to develop novel therapies for cervical cancer. Antisense oligo-deoxynucleotides and ribozymes targeting virus oncogenes were found to suppress growth of virus-related cancer cells both in vitro and in vivo. [7] [8] [9] Introduction of a short double-stranded RNA with a duplex region of 19 base pairs and two nucleotide 3 0 overhangs, known as a short-interfering RNA (siRNA), induces sequence-specific destruction of endogenous mRNA in mammalian cells, a phenomenon known as RNA interference (RNAi). Since the discovery of siRNA-induced RNAi in 2001, 10, 11 siRNAs have been utilized in reverse genetics and gene-targeting therapy. siRNA technology is completely different from others, in that siRNAs utilizes endogenous RNAi machineries that exert normal cellular functions. Studies have shown that introduction of those targeting E6 and E7 of hrHPVs resulted in growth suppression of virus-positive cancer cells. [12] [13] [14] [15] [16] [17] [18] [19] These results indicate the possibility of applying RNAi technology to therapeutic options for HPV þ cancer.
Although siRNA-induced target gene suppression was initially assumed to be highly sequence specific, it has become clear that siRNAs suppress unintended genes through RNA-induced silencing complex (RISC)-mediated cleavage of target mRNA or translation suppression, which is analogous to miRNA-mediated RNAi, [20] [21] [22] and stimulation of innate immune by type I interferon (IFN-I) and inflammatory cytokine responses. 23, 24 Suppression of such unintended genes by siRNAs is known as an off-target effect. RISC-mediated off-target effects are caused by a partial sequence complementarity between the guide strand and unintended genes, especially when excessive RISC is present. 25 Furthermore, some siRNAs have been reported to induce innate immune responses in a sequence-specific manner. 23, 24 For the purpose of applying siRNA technology to therapy for hrHPV-related cancers, it is mandatory to select siRNA sequences targeting E6 and E7 that have high levels of RNAi activity and minimal off-target effects. However, to date, no known HPV16 E6 or E7 siRNA sequence has been analyzed in detail in regard to those factors.
For the present study, we selected siRNA sequences targeting mRNA coding HPV16 E6 and E7 using siDirect software, based on guidelines established by Ui-Tei et al. 26, 27 From those findings, we developed highly effective siRNA sequences with maximum target specificity, and examined the siRNAs for RNAi activity and specificity using HPV16 þ and HPV16À cancer cells. Our results identified three E6 and E7 siRNAs compatible with most HPV16 variants, which were potent and specific in suppression of E6 and E7 expression, as well as growth of HPV16 þ cancer cells. Table 1 . Twenty-onebase ribonucleotides were synthesized, annealed in buffer (100 mM potassium acetate, 30 mM HEPES-KOH at pH 7.4, 2 mM magnesium acetate) and column-purified (Proligo Co. Ltd, Boulder, CO).
Materials and methods

Cell lines and plasmid transfection
One day before transfection, the cells were plated at a density of 5 Â 10 4 to 1 Â 10 5 cells per well in a six-well plate containing 2 ml of Dulbecco's modified Eagle's medium (DMEM) with 10% FCS. Various amounts of the siRNA were added with Opti-MEM I reduced serum medium (Invitrogen Corporation) up to 50 ml. For SiHa cells, SK-OV-3 cells, and their derivatives, 1.6 ml of Lipofectamine 2000 was diluted with Opti-MEM I reduced serum medium to 50 ml. For HeLa cells and their derivatives, 0.4 ml of Lipofectamine 2000 was diluted with Opti-MEM I reduced serum medium to 50 ml. Diluted siRNA and Lipofectamine 2000 were combined, incubated at room temperature for 20 min and then added to a 2-ml culture. The amount of Lipofectamine 2000 was changed in proportion to the culture medium volume. Transfection of siRNAs using Oligofectamine (Invitrogen Corporation) was performed according to the manufacturer's instructions.
Plasmid construction
The HPV16 E6E7 region from nt 231 to 858, DNE6E7 (231-858), was obtained by PCR amplification using pSV2-E6E7 (a gift from Dr T Kanda, National Institute for Infectious Disease, Tokyo, Japan) 28 as a template, and E6 sense and E7 antisense primers containing NotI sites at the 5 0 end were subcloned at the NotI site of the psiCheck-2 plasmid, with the resultant plasmid designated as 16NDE6E7/psiCheck-2. DNE6 region (231-559) and E7 region (562-858) were similarly cloned, and inserted between the XhoI and NotI sites of psiCheck-2, with the resultant plasmids designated as 16DNE6/psiCheck-2 and 16E7/psiCheck-2, respectively. An hLuc cDNA fragment isolated from psiCheck-2 was cloned into pcDNA3 at the HindIII and XbaI sites, and the resultant plasmid was designated as hLuc/pcDNA3. E7 of 16E7/psiCheck-2 was changed to an E7 variant carrying cytosine instead thymine at nt760 using GeneTailor Site-Directed Mutagenesis System (Invitrogen Corporation), and the resultant plasmid was designated as 16E7(760C)/psiCheck-2.
The primers used for plasmid construction were as follows: Not-HPV16_231s, 5 0 -GCGGCCGCATGACTT siRNAs were designated by the nucleotide position number of the 3 0 end of the guide strand. HPV16 classes and subclasses carrying a mismatch to the guide strand sequence are shown in the column of incompatible HPV16 class and subclass, with mismatched nucleotide positions also shown. The HPV16 classes and subclasses were as follows: Prototype (accession number K02718); European German 131 (EG131; accession number AF536179); East Asian (As; accession number AF534061); African 1 (Af1; accession number AF472508, AF536180); African 2 (Af2; accession number AF472509); Asian-American (AA; accession number AF402678); and North American I (NA1; accession number AF486325).
Underlines indicate an immunostimulatory motif. SiHa, HeLa and SK-OV-3 clones with constitutive expression of firefly luciferase SiHa, HeLa and SK-OV-3 cells were transfected with a firefly luciferase (Fluc) expression plasmid (hLuc/ pcDNA3) using Lipofectamine 2000 according to the manufacturer's instructions, and selected by cultivating in the presence of G418. The resultant stable clones expressing FLuc were designated as FL-SiHa-2, FL-SKOV-5 and FL-HeLa-1, respectively.
Reverse transcription-PCR
Isolation of DNA-free total RNA, synthesis of singlestranded cDNAs and PCR amplification were performed as previously described. 13 cDNA from mock-transfected cells was serially diluted and used as the standard. PCR assays were performed under the following conditions: denaturation at 94 1C for 5 min, followed by 22-26 PCR cycles (denaturation at 94 1C for 30 s, primer-annealing at 58 1C for 30 s, primer-extension at 72 1C for 30 s) and incubation at 72 1C for 5 min. Amplified products were separated on 2.5% agarose gels, stained with SYBR GOLD (Molecular probes, Eugene, OR) and analyzed using an FLA-2000 fluoro-image analyzer (Fuji Film, Tokyo, Japan). Band intensities were quantified using Image Gauge software (Fuji Film), and normalized to those of the b-actin band or those of 18S ribosomal RNA. PCR primers used for detection of E6 and E7 cDNAs are shown in Table 2 . Those for detection of b-actin cDNA were as follows: b-actin forward primer, 5 0 -CTCAC CATGGATGATGATAT-3 0 and b-actin reverse primer, 5 0 -TGGGTCATCTTCTCGCGGTT-3 0 . A pair of PCR primers for 18S ribosomal RNA was purchased from Applied Biosystems (Foster City, CA).
Immunoblotting
Cells at 2-5 Â 10 5 were washed with Dulbecco's phosphate-buffered saline (PBS) once, directly dissolved in 100 ml of sodium dodecyl sulfate (SDS)-gel loading buffer and incubated for 5 min at 95 1C. Ten microliters of each sample was then separated on a polyacrylamide gel containing 0.1% SDS. Immunoblot analysis was performed as described previously. 13 Bands were detected using an FLA-2000 fluoro-image analyzer (Fuji Film). Band intensities were quantified using Image Gauge software (Fuji Film) and normalized to those of the lamin A/C band. Anti-p21 WAF1/CIP1 (clone 70) and anti-lamin A/C monoclonal antibodies (clone 14) were purchased from BD Biosciences (San Jose, CA), while anti-p53 monoclonal antibody (DO-1) came from Santa Cruz Biotechnology Inc. (Santa Cruz, CA).
Analysis of in vitro cell growth and senescenceassociated b-galactosidase staining Cell viability was examined with a colorimetric assay using WST-8 (Cell Counting Kit 8, Dojin Laboratories, Kumamoto, Japan) according to the manufacturer's instructions. Senescence-associated b-galactosidase staining was performed using a Senescent Cell Staining Kit (Sigma-Aldrich Corporation, St Louis, MO).
In vivo tumor growth
To study the effects of the siRNAs on tumor growth in vivo, SiHa cells (2 Â 10 7 cells) were subcutaneously inoculated into 6-week-old NOD/SCID mice, after which tumors slowly formed at the injected site. Six weeks after the inoculation, siRNAs complexed with AteloGene (Koken Co. Ltd, Tokyo, Japan) according to the manufacturer's instructions were directly injected into the tumors at a dose of 500 pmole per tumor every 7 days (n ¼ 6 for each group). Thirty-five days after the first siRNA injection, the mice were killed according to the UKCCCR guidelines, and each tumor was excised and weighed. Tumor weight differences were analyzed for significance using a Student's t test, with Po0.05 considered to indicate statistical significance.
Results
Selection of HPV16 E6 and E7 siRNA sequences A total of 17 siRNA sequences targeting the E6 and E7 coding regions of HPV16 (Table 1, Figure 1a) were selected using siDirect software, 27 which is based on guidelines for designing siRNA sequences for mammalian RNAi. 26 All of the sequences had structural characteristics of functional siRNA 26, 30, 31 and contained at least three mismatches in the guide strand with the nonredundant sequence set of human genes (mismatch tolerance 3). 27 Five siRNAs (117, 128, 324, 326, 615) containing nucleotides that differed among HPV16 classes and subclasses were excluded (Table 1, Supplementary Table  1) , and a total of 10 siRNAs targeting different regions of E6 and E7 were chosen from the remaining 12 for this study, as follows: 233, 243 and 244, targeting E6-E7 mRNA, but not E6*I-E7 or E6*II-E7 mRNA; 493, 497 and 501, targeting E6-E7 and E6*I-E7 mRNA, but not E6*II-E7 mRNA; 573, 698, 707 and 752, targeting all three splicing variants. After revision of the nonredundant sequence database, two siRNAs (244, 501) were reclassified as mismatch tolerance 2. (Figure 1c) . The RNAi activities of siRNA 493 and 573 toward RLuc-DNE6E7 were low (data not shown), and thus reevaluated using RLuc-DNE6 and RLuc-E7, respectively (Figures 1d  and e) . All the siRNAs examined showed high RNAi activities with IC 50 values between 0.012 and 0.380 nM, which suggested that the selected siRNAs efficiently formed an RISC and degraded the artificial RLuconcogene fusion mRNAs.
Effects of HPV16 E6 and E7 siRNAs on endogenous mRNAs coding E6 and E7
To examine the effects of the siDirect-selected siRNAs on endogenous E6 and E7 expression, SiHa cells were transfected with the siRNAs (50 nM) for 48 h, then E6 and E7 expression was analyzed by RT-PCR. As shown in Figure 2a , PCR amplification of cDNA from control siRNA-transfected cells with a pair of E6-specific primers (E6_104s and E6_558as in Figure 1a , Figure 2b , all tested siRNAs showed moderate-tostrong growth suppression toward FL-SiHa-2 cells, while they also inhibited the growth of HPVÀ cells (FL-HeLa-1, FL-SKOV-5) to various degrees. Among them, 698, 186 and 535 strongly suppressed the growth of HPV16À cells, especially FL-HeLa-1 cells by more than 70%, suggesting that these siRNAs had a strong nonspecific growth inhibition characteristic.
To determine if decreased siRNA concentrations alleviated nonspecific growth suppression without compromising the specific growth inhibition, the dose effects of siRNA 497, 573, 707, 752, 203 and 222 were examined. At concentrations from 1 to 5 nM, all siRNAs suppressed the growth of FL-SiHa-2 cells in a dose-dependent manner (Figure 3c ), except for 573, which exhibited similar levels of growth suppression at these concentrations. At a concentration of 1 nM, 497, 573 and 752 inhibited FL-SiHa-2 cell growth by more than 90%, while the growth suppression of HPV16À cells decreased to less than 35% (Figures 3a and b) . These results suggest that 497, 573 and 752 were able to induce a potent and specific growth inhibition toward HPV16 þ cells at 1 nM. In contrast, 707, 203 and 222 showed less potent growth inhibition of FL-SiHa-2 cells at 1 nM.
Dose-dependent effects of E6 and E7 siRNAs on endogenous E6-E7 mRNA
To confirm that the observed siRNA-induced growth inhibition was associated with E6 and E7 downregulation, FL-SiHa-2 cells were transfected with mock, control, E6 and E7 siRNAs (752, 203, 535) for 72 h, after which E6 and E7 expression was examined by RT-PCR using primer pairs for each (E6; 16E6s104 and 16E6as375, shown in Figure 1a , Table 2 and E7; 16E7s562 and 16E7as855). As shown in Figure 3d , siRNA 752 suppressed the level of E7 mRNA to 11, 19 and 43% at 25, 5, and 1 nM, respectively, as compared to the control siRNA-transfected cells. Furthermore, siRNA 752 decreased the E6 mRNA level to 29, 48 and 52%, respectively. In addition, two previously reported siRNAs (203, 535) showed comparable RNAi activities toward E6 and E7 mRNA. Also, 186 decreased the expression levels of both E6 and E7 mRNA, whereas 222 decreased only that of E6 (Figure 3e ), which has been reported previously.
12,13 siRNA 375 14 and 660 12 were less potent and suppressed E6 and E7 expression by only 50% (data not shown).
Induction of p53 and p21
WAF1/CIP1 by E6 and E7 siRNAs Next, we examined the downregulation of E6 protein in the siRNA-transfected cells by analyzing the expression of p53, since there is no high affinity anti-E6 antibody capable of detecting low E6 expression presently available. p53 is an E6 target protein that degrades p53 through the ubiquitin-proteasome pathway, 2,3 while E6 knockdown restores its expression. The dose-dependent effects of siRNA 497, 573 and 752 on p53 levels were examined in FL-SiHa-2 cells using immunoblot analysis (Figures 4a-c) . siRNA 497 and 573 caused a substantial accumulation of Induction of senescence in cervical cancer cells treated with siRNA 573 and 752 To clarify the mechanism by which E6 and E7 siRNAs induced growth suppression in cervical cancer cells, FL-SiHa-2 cells were transfected separately with siRNA 573 and 752 at 5 nM every 3 days, with cell morphological changes closely observed under an inverted microscope. Seven days after the first transfection, both 573-and 752-siRNA-transfected cells become larger and flatter, whereas mock and control siRNA-transfected cells did not change (data not shown). In 12-14 days after the first transfection, most E7 siRNA-treated cells were found to have long cytoplasmic projections and became positive for senescence associated b-galactosidase (SA b-gal) staining (Figure 5a) . Furthermore, SA b-gal activity was detected in the perinuclear areas of the E7 siRNA-treated cells. These results suggested that the E7 siRNAs caused growth inhibition in HPV16 þ cells by inducing cellular senescence.
Inhibition of tumor growth initiated by SiHa cells in NOD/SCID mice by siRNA 752 SiHa cells at 2 Â 10 7 were subcutaneously inoculated into NOD/SCID mice. Six weeks after inoculation, palpable tumors had formed in all of the mice, and control or 752 siRNA complexed with atelocollagen was directly injected into each tumor every 7 days. Thirty days after the first siRNA injection, the tumors were excised and weighed. As shown in Figure 5b , tumors treated with siRNA 752 had significantly lower weights than those treated with control siRNA (Po0.001, mean weight: 2.73±0.66 g in the control siRNA-treated group; n ¼ 6 versus 1.03 ± 0.29 g in the 752-treated group; n ¼ 6), which showed that treatment with siRNA 752 decreased in vivo tumor growth caused by SiHa cells.
Effects of E7 siRNAs on E7 variant expression
Three siRNAs (497, 573, 752) were chosen from 10 siDirect-selected siRNAs based on their high levels of RNAi activity and specificity. We then performed a literature search for E6 and E7 variant sequences that had a mismatch with these siRNAs. [32] [33] [34] [35] [36] [37] A minor E7 variant, E7(760c), which contained cytosine instead of thymine at nucleotide 760, 35 was found to have a mismatch with siRNA 752. We tested the RNAi activity of 752 toward the expression of E7(760c) using a reporter gene assay. SiHa cells were transfected with the RLuc-E7(760c) fusion mRNA expression plasmid along with siRNA 752 or 752c, which was perfectly matched to E7(760C) (Supplementary Figure 1 ). Although both 752 and 752c suppressed the expression of RLuc-E7(760c), the 1-base mismatch decreased the IC 50 value by fivefold (0.021 nM of 752c siRNA versus 0.107 nM of 752 siRNA). This result suggested that perfect sequence complementarity between the guide strand and target mRNA, especially in the middle portion of the guide strand, is important for RISC enzyme efficiency.
Discussion
With the aim of identifying new drug candidates for HPV16 infection and virus-related cancer, we designed siRNAs targeting HPV16 E6 and E7 oncogenes using siDirect computer software, 27 and analyzed their RNAi activities and specificity. The siDirect software is based on guidelines for the selection of effective siRNA sequences developed by Ui-Tei et al. 26 and enables selection of siRNAs with structural advantages for efficient loading of guide strands into RISC, 26, 30, 31 as well as a minimal number of off-target candidates from a database of nonredundant sequence sets of human genes. In the present study, reporter gene assays using luciferase-target fusion gene expression plasmids and our designed siRNAs revealed that all siDirect-designed siRNAs possessed high RNAi activity, as expected. However, the levels of suppression of endogenous E6-E7 mRNA in HPV16 þ cancer cells varied among them. Five of the 10 siRNAs suppressed the expression of target mRNA by more than 75%, while the others showed suppression of 35-65%. These results suggest that RISC loading is not a sole determinant of RNAi activity and other factors, such as accessibility of RISC to the target sequence, [38] [39] [40] target cleavage and release of cleaved RNA, might be involved in the RNAi activities of designed siRNAs. Target accessibility is assumed to be due to the RNA secondary structure and interaction of target mRNA with other molecules. Thus, structural prediction of target mRNA would be beneficial for designing siRNAs.
Despite initial reports showing a high specificity for siRNA-directed RNAi, 10, 11 recent studies have revealed that siRNAs induce off-target effects by several mechanisms. 20, 25, 41 An siRNA can tolerate some mismatches with its target mRNA when undergoing directed target cleavage, though enzyme efficiency decreases with increases in the number of mismatches. 25 In fact, we observed that a single nucleotide mismatch in the central portion of an siRNA targeting mRNA caused a fivefold decrease in the value of IC 50 . siRNA sequences selected by siDirect software have at least three base mismatches with nonredundant sequence sets of human genes. Therefore, some off-target effects exerted through RISC cleavage may be attenuated by lowering the siRNA concentration.
mRNA that has a 3 0 untranslated region containing a sequence complementary to nucleotide 2-7 of the 5 0 end of the guide strand, analogous to the seed region of miRNA, can be a collateral target for siRNA-mediated translation inhibition. [20] [21] [22] Those studies also suggested that all siRNAs potentially possess miRNA-like activities. To minimize such off-target effects, complementarity between the guide strand and human genes should be carefully analyzed. Chemical modifications of siRNAs, such as a 2 0 O-methyl ribose modification, have been reported to reduce the miRNA-like off-target effect without compromising RNAi activity. 42 siRNAs can also exert unintended effects through IFN-I and inflammatory cytokine production. Receptors of siRNAs for immunostimulation include double-stranded RNA-dependent protein kinase (PKR) and toll-like receptors (TLRs), such as TLR3, TLR7 and TLR8. siRNAs with sequences of 5 0 -GUCCUUCAA-3 0 , 5 0 -UGUGU-3 0 and 5 0 -UGUCU-3 0 have been shown to stimulate mouse TLR7 and, most likely, human TLR8. 23, 24 Among the E6 and E7 siRNAs selected in our study, siRNA 497 contained the 5 0 -UGUCU-3 0 sequence. Activation of TRLs may be bypassed by delivery of an siRNA in a cholesterol-conjugated 43 or atelocollagen-complexed form, 44 as well as following chemical modification of the RNA backbone. 45 The mechanism by which the present siRNAs exhibited their off-target effects on HPV16À cells was not revealed. However, nonspecific growth suppression of three of the siRNAs (497, 573, 752) was significantly improved without compromising their strong growth suppression of HPV16 þ cells by reducing the siRNA concentration to as low as 1 nM. To further improve the off-target effect, we are now working on backbone modification of these siRNAs, which has been reported to attenuate miRNA-like activity and cytokine response. 42, 45, 46 miRNA has been implicated in diverse regulation pathways, including control of cell differentiation, apoptosis, cell proliferation and organ development. Long-term use of a high dose of siRNA might disturb these normal functions of miRNA by saturating the limited source of RNAi machinery. Therefore, it is important to administer a minimal dose of synthetic siRNA with high RNAi activity. A molecular abundance of human miRNA in HeLa cells has been reported. 47 The calculated intracellular concentrations of different miRNAs, including miR-22, miR-16, let-7 and miR-21, in HeLa cells ranges from about 0.1 to 2 nM, when assuming that the cell volume is about 10 pl. Therefore, administration of E6 and E7 siRNAs that do not exceed an intracellular concentration of 2 nM should safely exert an antitumor effect without disturbing endogenous RNAi.
In the present experiments, we identified three new siRNAs (497, 573, 752) that possessed high RNAi activities toward E6 and E7 expression, and whose growth inhibition effects were potent and specific to HPV16 þ cancer cells. Furthermore, the sequences of those siRNAs showed full complementarity with all HPV16 classes and subclasses. We also performed a literature search to determine if the siRNAs were compatible with E6 and E7 variants found in patient samples from various countries (total 991 cases). [32] [33] [34] [35] [36] [37] Three variants were found in the same series of patients from Hong Kong (255 patients), 35 with E6(517G), in which thymine at nt 517, located at the 5 0 end of the 497 guide strand, was changed to guanine, found in three patients, E7(757T), which carried thymine instead of cytosine at nt 757, found in one patient and E7(760c), which contained thymine instead of cytosine at nt 760, found in seven patients (3.1%). These variants were not seen in patients from other areas. Thus, siRNA 497, 573 and 752 are considered to be compatible with most HPV16 variants.
Deregulation of E6 and E7 expression is a necessary cause of malignant transformation, and additional genetic alterations accumulate before progression to carcinoma development. Studies using antisense oligo-DNA, ribozymes, transcriptional suppression by forced E2 expression, and siRNAs have revealed that inhibition of E6 and E7 expression is sufficient to cause growth suppression of HPV-related cancer cells. [7] [8] [9] [12] [13] [14] [15] [16] [17] [18] 48 In the present study, E6 and E7 siRNA-induced growth suppression was associated with morphological and cytochemical characteristics of cellular senescence. Our results are consistent with other studies, which also demonstrated that downregulation of E6 and E7 causes in vitro and in vivo growth suppression, as well as cellular senescence. 15, 16, 48 Induction of senescence might be caused by reactivation of PML, which has been shown to be a mediator of senescence and a target of E7. 6 Recently, human fibroblasts immortalized by a temperature sensitive SV40 large T antigen were reported to undergo irreversible senescence by a reactivated p16
INK4a /Rb pathway after incubation at a nonpermissive temperature for a specific period of time. 49 The functional similarity between SV40 large T antigen and hrHPV E6E7 suggests that siRNA-mediated senescence might be irreversible.
Infection with hrHPV causes intraepithelial precancerous lesions in the cervix, termed cervix intraepithelial neoplasia (CIS). 50 High-grade lesions (CIS grade 3) express deregulated hrHPV oncogenes and eventually develop into invasive cervical cancer after a long latency without spontaneous regression. Downregulation of the virus oncogenes using an siRNA could reverse the neoplastic phenotype and also prevent E7-induced genetic alterations. In hrHPV-infected lesions, replication of HPVs relies on E7 expression. 5 Thus, an siRNA targeting E7 may be able to inhibit virus replication as well as propagation. CIS lesions exist within epithelium and are easily accessible. 51 Furthermore, local siRNA administration could help to avoid its hazardous systemic offtarget effects. Therefore, we consider such lesions to be ideal targets of RNAi therapy.
The US Food and Drug Administration (FDA) approved a preventive HPV vaccine for immunization of women between 9 and 26 years of age, with a second vaccine now being tested. These HPV vaccines will eventually reduce the incidence rates of viral infection and cervical cancer. However, there are currently no effective therapies for individuals infected with HPV and a small fraction of those patients will develop cancer in a decade or two. 50 Notably, immunosuppressed patients such as organ transplant recipients and HIV-infected patients, whose response to an HPV vaccine is unknown, have greater propensity for cervical cancer and anal cancer. 52, 53 It is also unclear how long the protection provided by the HPV vaccines will last. Therefore, RNAi therapy using potent and specific siRNAs will benefit patients infected with HPV. Also, in parallel with HPV vaccination, RNAi therapy may speed up the reduction in rates of incidence of HPV infection and cervical cancer.
